Foresite Capital Management I’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-66,810
Closed -$13.8M 3
2021
Q3
$13.8M Hold
66,810
10.84% 2
2021
Q2
$14.2M Hold
66,810
8.55% 2
2021
Q1
$12.1M Hold
66,810
6.11% 2
2020
Q4
$7.45M Hold
66,810
3.92% 2
2020
Q3
$7.24M Buy
+66,810
New +$8.14M 2.04% 2
2014
Q2
Sell
-66,810
Closed -$6.05M 9
2014
Q1
$6.05M Hold
66,810
4.25% 7
2013
Q4
$6.84M Buy
+66,810
New +$4.72M 6.65% 6

Other funds holding NVAX

Foresite Capital Management I's NVAX Position: Q4 2021 in Review

Foresite Capital Management I sold out of Novavax (NVAX) in Q4 2021, closing a stake of 66,810 shares — an estimated $13.8M sold.

Foresite Capital Management I first reported a position in NVAX in Q4 2013 and held it in 7 quarters. The position peaked at $14.2M in Q2 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

  • Foresite Capital Management I reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
  • Foresite Capital Management I sold 66,810 Novavax shares in Q4 2021, an estimated $13.8M.
  • Foresite Capital Management I first reported a position in Novavax in Q4 2013 and held it in 7 quarters.
  • Foresite Capital Management I's Novavax position peaked at $14.2M in Q2 2021.
  • 429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on Foresite Capital Management I's 13F filing for Q4 2021, filed 11 Feb 2022.